Immuno-Oncology | Specialty

Dr. Sznol on Patient Selection for Combination Therapy in mRCC

May 9th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.

Dr. Liu on the Potential of Pembrolizumab in SCLC

May 8th 2019

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the potential of pembrolizumab in the treatment of patients with small cell lung cancer.

Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC

May 3rd 2019

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.

Dr. Nadler Discusses the IMpower131 Study in Squamous NSCLC

May 2nd 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.

Frontline Cabozantinib Plus Nivolumab/Ipilimumab Explored in Phase III RCC Trial

May 2nd 2019

In an effort to improve outcomes for intermediate- or poor-risk patients with renal cell carcinoma, the phase III COSMIC-313 trial is being initiated, which will evaluate cabozantinib (Cabometyx) in combination with nivolumab and ipilimumab in patients with previously untreated advanced disease.

The KEYNOTE-775 and Future of Endometrial Treatment

April 30th 2019

The Role of Lenvatinib Plus Pembrolizumab

April 30th 2019

The KEYNOTE-146 Trial

April 30th 2019

Advancements in Chemotherapy & PD-1 Inhibitor Therapies

April 30th 2019

Evolving Treatments for Advanced Endometrial Cancer

April 30th 2019

An Evidence-Based Argument Is Often the Fastest Route to Immunotherapy Authorization

April 30th 2019

Many oncology practices are learning lessons about the importance of persistence, persuasion, and creativity in getting I/O drugs to the patients who need them.

Dr. Nadler Discusses Role of PD-L1 in Squamous NSCLC

April 29th 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the role of PD-L1 in patients with squamous non–small cell lung cancer.

Potential Evolutions in the TNBC Treatment Paradigm

April 29th 2019

Applying IMpassion130 Data to TNBC Management

April 29th 2019

I-O in TNBC: IMpassion130 Trial Design and Results

April 29th 2019

A Background on TNBC and Management

April 29th 2019

Dr. Mok Discusses Updated Data With Pembrolizumab in NSCLC

April 25th 2019

Tony Mok, MD, professor, Department of Clinical Oncology, Chinese University of Hong Kong, discusses updated data with pembrolizumab in patients with non–small cell lung cancer.

Dr. Garassino Discusses PROs With Durvalumab by PD-L1 Expression in Stage III NSCLC

April 25th 2019

Marina Chiara Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses patient reported outcomes with durvalumab by PD-L1 expression in patients with stage III unresectable non–small cell lung cancer.

Dr. Jonasch on Single-Agent Pembrolizumab in Non-Clear Cell RCC

April 24th 2019

Eric Jonasch, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the use of single-agent pembrolizumab in the treatment of patients with metastatic non–clear cell renal cell carcinoma.

Dr. Sonpavde on the Role of Durvalumab in Platinum-Refractory Bladder Cancer

April 24th 2019

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the role of durvalumab in the treatment of patients with platinum-refractory bladder cancer.